Updates from Drug Programs in Clinical Trials
At the Annual SMA Conference, representatives from six of the seven programs currently in clinical trials gave an update on their programs. Of these six programs, four—gene therapy, ISIS-SMNRx, RG7800, and LMI070—treat the underlying genetics of SMA. Gene therapy aims to correct the mutation in the SMN1 gene that causes SMA, and the other three […]
Updates from Drug Programs in Clinical Trials Read More »